Mediso Launches Next Generation MRI Spectrometer spinScan®

Mediso released their next generation MRI spectrometer spinScan® the successor to the previously used console in the nanoScan® MRI product line. The new spectrometer was optimized for MRI applications delivering an ultra-low-noise expandable RF front-end and real-time dynamic shimming.

The spectrometer is interfaced with three Mediso developed software applications to deliver a complete MRI workflow: the Sequence Development Platform for absolute control over the pulse sequences and reconstruction algorithms, the FDA approved and clinically validated InterView™ FUSION and Nucline™ for routine acquisition planning, reconstruction, image post-processing and evaluation.

Gergő Bagaméry, Director of Preclinical Product Development at Mediso commented: “Our main goal was to have a dedicated MRI spectrometer that is optimized for image quality, and works seamlessly with our clinically validated software platforms. We believe it is a big jump in performance for our research scanners as well as perfect platform for a potential clinical / OEM product line.”

The spinScan® spectrometer is based on a technology that has been continuously developed for 10+ years, featuring an FPGA SoC platform with highly scalable transceiver architecture enabling more than 128 receiver channels and microsecond gradient resolution with closed-loop control via high-speed optical interfaces. Eddy current compensation is realized through digital cross term pre-emphasis adjustment allowing for improved EPI image quality. The spinScan® spectrometer features Mediso’s extensive pulse sequence library with a wide range of readily optimized imaging protocols including all relevant anatomical sequences as well as high-end neuroimaging and spectroscopy protocols.

The console creates a future proof platform for all nanoScan® MRI systems, especially empowering the standalone MRI’s used for high-end preclinical research applications.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”